News in brief - May 2013

Other new launches, licence changes and prescribing updates relevant to general practice.

The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
The integrase inhibitor raltegravir (Isentress) provides a new treatment option for paediatric patients with HIV
  • A generic equivalent of Malarone (atovaquone/proguanil) has been launched for the prophylaxis and treatment of acute uncomplicated P. falciparum malaria.
  • The antidiabetic combination tablet Komboglyze (metformin/saxagliptin) is now indicated for use in combination with a sulfonylurea when a sulfonylurea plus metformin is inadequate.
  • A licensed oral suspension of clobazam, Tapclob, has been launched for use as an adjunct in epilepsy.
  • Isentress (raltegravir) is now available as chewable tablets to treat HIV-1 infection in children from the age of 2 years.
  • The cannabis-based MS spasticity treatment Sativex has been reclassified as a Schedule 4 CD, meaning that it can now be prescribed as a POM without any restrictions.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in